Key Market Indicators
By 2026, Norwegian diabetes medicine sales are projected to reach around $183 million, a 2.4% increase from 2021. This growth is an average year-on-year rate since 2007. Norway placed 17th in the 2021 ranking, with Finland ahead at $159.6 million. Canada, Spain and Italy respectively came in second, third and fourth. Norwegian insulin imports are estimated to drop by 6.8% to $5.1 million in 2026, from $7.8 million in 2021. Since 1998, demand has declined 16.4% each year. Exports of insulin from Norway fell 99.9% in 2018 to just $6,000, from $4.1 million in 2017. Since 2006, supply has decreased 78.4% year-on-year. Norway ranked 56th in 2018, with Belarus ahead at $6,000. France, Italy and China were numbers two, three and four respectively.
